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Abstract
Introduction: The study objective was to determine which antibiotics are optimal in the treatment of children with 
complicated acute bronchitis with bronchospasm. For that, a Monte-Carlo simulation was conducted.
Materials and methods: The retrospective study was performed on the antibiotic therapy data from 1604 medical 
records of inpatients from Nizhny Novgorod (Russian Federation) medical centers admitted with acute bronchitis with 
bronchospasm. The treatment programs involved cephalosporins, inhibitor-protected penicillins, and macrolides. The 
starter drug was selected empirically considering the possible etiology and sensitivity of the presumed pathogen to the 
antimicrobial agents. The input data for the model (Monte-Carlo simulation) were the costs of antibiotic therapy and the 
probability of the clinical outcome (recovery, or the absence of effect). The probabilities of the clinical outcome were 
described with β-distribution, while the costs distribution was described using gamma-distribution.
Results and discussion: Most positive clinical outcomes were observed with the use of macrolides, which also provided 
the lowest CER (cost-efficiency ratio), and are, therefore, optimal pharmacoeconomically. During the trial, the confidence 
intervals were evaluated for the clinical efficiency (95% CI of the β-distribution curve). The least interval of probable 
clinical efficiency for the investigated nosology was found for macrolides, which indicates their high clinical efficiency.
Conclusion: Monte-Carlo method visualizes the results of clinical-economical evaluation of any medical technology 
in one disease compared to another. That is of value for the clinical pharmacologists and health professionals selecting 
the drugs for healthcare facilities.
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Introduction
Acute obstructive bronchitis is frequent in children. The 
repeated (2–3 times or more within one year) episodes 
of bronchitis with bronchospasm are a recurrent type of 
obstructive bronchitis. The pathogenesis of recurrent ob-
structive bronchitis is complex. Infectious factors are of the 
paramount importance. Bacterially induced inflammation 
develops through acute respiratory viral infection (ARVI). 
The bacterial overgrowth contributes to further inflamma-
tion, both by damage to the bronchial structure itself and 
by activation of enzymes in inflammatory cells, resulting 
in mucociliary clearance impairment. This, in turn, promo-
tes the development of pan-bronchitis and peri-bronchitis 
and contributes to the development of deforming bronchi-
tis. The antibiotic therapy plays a significant role, not only 
resolving the symptoms of acute inflammation, but also 
eradicating the pathogen, eventually decreasing the num-
ber of repeated bouts, the inter-exacerbation interval, thus, 
improving the patients’ quality of life. The starter drug is 
selected empirically, considering the probable etiology and 
sensitivity of the presumed pathogen to antimicrobials.
One of the major directions when planning and defin-
ing the priority therapeutic measures is a clinical and eco-
nomic analysis of a drug therapy. Using the results of this 
clinical and financial evaluation can optimize a drug pre-
scription system, prevent the prescription of unnecessary 
drugs, and also determine the most effective medicines 
for a specific nosology. Comparative assessment of the 
quality of two and more methods of prevention, diagnos-
tics, medical and non-medical treatment is the primary 
method of the clinical and economic analysis.
While an experiment on the real object is often impos-
sible, pharmacoeconomics frequently uses simulation, 
in particular, Monte-Carlo method (Barton et al. 2004). 
Monte-Carlo simulation was also used to evaluate the 
incidence at the population level (Stuebe et al. 2017), to 
compare the costs and efficiency of empirical treatment 
including ceftolozane/tazobactam or piperacillin/tazobac-
tam in gram-negative hospitalized patients (Kauf et al. 
2017). Monte-Carlo simulation is a common name for a 
group of numerical methods based on obtaining a large 
number of representations of stochastic (random) process, 
which is formed in such a way that its probabilistic char-
acteristics match the similar values of the task at hand. 
The Monte-Carlo method reproduces and studies the be-
havior of all the components of the system under study 
(Briggs et al. 2007).
The study was aimed to determine the clinically and 
economically optimal antibiotics for the treatment of 
acute bronchitis complicated with bronchospasm in chil-
dren using Monte-Carlo simulation.
Materials and methods
The analysis included retrospective evaluation of 2 519 
physicians’ prescriptions from the case histories from 
2008 to 2014 in three medical centers of Nizhny Novgorod 
(Russian Federation). The patients were from 0 to 18 years 
old. To 31.0% (n=781) of the patients, no antibiotics were 
prescribed. Also, the study excluded case histories of the 
patients in whom the antibiotic therapy had caused side 
effects in the form of allergic reactions (5.3%, n=134). No 
cases of dysbiosis were noted, as the antibiotic therapy 
was administered along with probiotics. The study popu-
lation included only the case histories from 1604 patients 
who had been receiving the antibiotic therapy.
In this study, the number of boys with acute bronchi-
tis with bronchospasm exceeded the number of girls by 
1.5 times. The narrower airways, an increased tonus of 
smooth muscles of the bronchial tree and a higher level 
of IgE (immunoglobulin E) explain an increased risk of 
developing acute bronchitis with bronchospasm in boys 
relative to girls.
The highest number of cases of complicated bronchi-
tis with bronchospasm was observed in children under six 
years old. The patient distribution by age was: 1) 0–1 y/o 
– 663 (41.3%); 2) 1–3 y/o – 550 (34.3%); 3) 3–6 y/o – 312 
(19.5%); 4) > 6 y/o – 79 (4.93%). That predominance can be 
explained by an immature immune system of the children, 
and by their susceptibility to colds often complicated by 
bronchitis (which can further lead to bronchial obstruction).
The start drug was chosen empirically, considering the 
probable etiology and sensitivity of the presumed patho-
gen to antimicrobials (Table 1). The antibiotics in acute 
bronchitis in children were prescribed for the following 
reasons: severe intoxication, fever lasting more than three 
days, the presence of an obstructive syndrome, clinical 
signs of bronchitis, an early age of the patient, and a 
Table 1. Dosage regimen and treatment duration for the used antibiotics.
Medication (INN (International Nonproprietary Name)) Average dosage, mg (IU) Frequency and route of administration 
Average treatment 
duration, days 
Cephalosporins Cefotaxime 600 (610±4.42) Twice daily, im 8.5
Ceftriaxone 625 (626.25±3.96) Once daily, im 8.5
Cefuroxime 180 (182±1.47) Twice daily, im 8.5
Cefazolin 900 (896.12±1.71) Three times daily, im 8.5
Inhibitor-protected penicillins Amoxicillin/clavulanate 270 (271.58±1.38) Twice daily, oral intake 7
Macrolides Azithromycin 250 Once daily, orally 4
Clarithromycin 250 Twice daily, orally 7
Spiramycin 375 (374.71±4.75) thsd. IU Twice daily, orally 9
Midecamycin 350 (350±3.84) Twice daily, orally 10
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prolonged course of the disease. The concurrent diseas-
es (otitis, sinusitis, tonsillitis) were observed in 32.6% 
(2008), 27.5% (2009), 32.3% (2010), 30.7% (2011), 
29.8% (2012), 29.2% (2013), and 31.2% (2014) of the 
cases. The number of children with recurrent bronchial 
obstruction was 40.7%. Currently, the most common an-
tibacterials to treat bronchitis were three groups of antibi-
otics, so-called ”gold standard drugs”: penicillins (amox-
icillin, inhibitor-protected penicillins), II–III generation 
cephalosporins, and macrolides.
The cost of an antibiotic treatment course was calculated 
by multiplying the average dosage of the drug (mg) by ad-
ministration frequency, by the average treatment duration 
(days), and by the price of 1 mg of the antibiotic (US$).
The average duration of cephalosporines therapy was 
8.5 (8.51±1.41) days, of inhibitor-protected penicillin 
(amoxicillin/clavulanate) – 7 days, and of macrolides, it 
varied from 3–5 days for azithromycin to 10 days for mide-
camycin. With ineffective antibiotic treatment, the treat-
ment duration could be increased to 10–13.5 days. In this 
case, after a course of antibiotic therapy, the disease symp-
toms persisted in 35.7% of the cases. In 37.1% of these pa-
tients, another course of antibacterial drugs of a different 
class (sequential antibiotic therapy) was prescribed. The 
following changes were made: cephalosporin/macrolide 
(76.5%), inhibitor-protected penicillin/macrolide (15.0%), 
and cephalosporin/inhibitor-protected penicillin (8%). The 
sequential antibiotic therapy conduced to the favorable 
clinical outcomes in 100% of the cases.
The efficiency of an antibiotic therapy was evaluated 
by the rate of positive clinical outcomes, using the initial-
ly prescribed drug without adding any other ethiotropic 
drugs. Positive clinical outcomes, such as ”recovery” or 
“significant improvement”, were registered by a physi-
cian in each case history. The clinical outcome was con-
sidered positive in cases of body temperature normaliza-
tion, elimination of intoxication, elimination of bronchial 
obstruction, and normalization of humoral activity.
When using Monte-Carlo method for the cost-effec-
tiveness analysis, a mathematical model was created for 
each treatment method to evaluate. Using this model, the 
cost-effectiveness ratio was calculated for each of the 
treatment methods under comparison. This analysis was 
performed in three stages:
• constructing a mathematical relationship between 
the data sought for and the variable parameters, 
such as the cost of medical resources, the probabili-
ty of the clinical outcome, etc.;
• estimating types of mathematical distributions to 
describe the distribution of particular variable pa-
rameters:
• Monte-Carlo simulation itself.
The input data for the model included the costs of an 
antibiotics therapy, as well as the probabilities of clinical 
outcomes for different methods of treatment. There were 
two possible clinical outcomes of the antibiotics therapy: 
1) positive clinical effect (recovery), or 2) adverse clinical 
effect. It was assumed that all the experimental data were 
as a set of random numbers that are subject to certain statis-
tical distributions. To calculate the probability of a clinical 
outcome, beta-distribution was used, and to describe costs, 
a gamma-distribution was used. Beta-distribution is typi-
cally used when describing probabilities for the binomial 
data (ill or healthy). In the probability theory and statistics, 
beta-distribution is used as a two-parameter family of abso-
lutely continuous distributions. It is limited to the interval 
from 0 to 1 and is characterized by two parameters, α and β. 
Parameters of beta-distribution are calculated on the basis 
of the existing experimental data. Considering the sample 
of n events (the patients who used the drug studied), and 
taking the number of successful uses as r (the number of 
positive clinical outcomes when using the examined anti-
biotic), then the parameters α and β are defined as α = r, β= 
n – r. Thus, beta-distribution fits the objectives of the study.
As noted above, the costs are usually described by 
using gamma-distribution. In the probability theory, it is 
considered as a two-parameter family of absolutely con-
tinuous distributions.
This choice was based on the assumption that the gam-
ma-distribution is defined and is continuous in the range from 
0 to infinity, which is more appropriate to describe costs.
Based on beta- and gamma-distributions with the pa-
rameters set for each antibiotic, samples were generated, 
containing 1000 random uses each. Then the cost-effec-
tiveness ratio was calculated in each sample.
Results and discussion
In the analyzed period, two groups of antibiotics: 
β-lactams (cephalosporins, protected penicillins), and 
macrolides were used for treatment of acute bronchitis 
with bronchospasm. The injections of cephalosporins 
were prescribed most often (57.8%).
From the cephalosporins, cefotaxime (56.9%), ceftri-
axone (23.0%), cefuroxime (13.8%), and cefazolin (6.3%) 
were mostly used. Cefazolin was excluded from the fur-
ther analysis due to the low frequency of its presciprion 
(to fewer than 100 patients) and, therefore, the impossi-
bility to evaluate its clinical and economic component.
Of the protected penicillins group, the only drug used 
was amoxicillin/clavulanic (16.3%). Macrolides were 
prescribed in 25.9% of the cases. Of the macrolides, 
azithromycin (65.6%), clarithromycin (9.5%), spiramycin 
(18.9%), and midecamycin (6%) were mainly used.
The antimicrobial therapy of acute bronchitis with 
bronchospasm was most efficient (“recovery”) when us-
ing macrolides. The clinical outcomes “significant im-
provement” and “recovery” after using cephalosporins 
and protected penicillins were observed when there were 
co-morbidities, such as otitis, sinusitis, and tonsillitis, 
which are often accompanied by fever and intoxication.
Low efficiency of cephalosporins and protected penicil-
lins in the treatment of acute bronchitis with bronchospasm 
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without any co-morbidities can indicate an allergic, atypi-
cal bacterial, or viral nature of acute bronchitis with bron-
chospasm (Table 2).
During the study, the models for β-lactam antibiot-
ics (protected penicillins and cephalosporins) were con-
structed (Fig. 1).
Figure 1 shows that the cefuroxime course is the most 
expensive. The least expensive is the course of amoxi-
cillin/clavulanic acid. The most effective are the courses 
of cefotaxime, with the probability of a positive clinical 
outcome when using this drug being much higher in com-
parison with the other drugs.
To compare the clinical efficacy of β-lactam antibiot-
ics, the curves of beta-distributions of the effectiveness of 
the studies antibiotics were constructed (Fig. 2).
If the curve is narrow and sharply peaked, the meas-
urement results (in this case, the probability of a posi-
tive clinical outcome) are highly reproducible. When the 
curve is broad and shallow, the reproducibility of the drug 
effect is low. The simulation showed that clinically and 
economically, the most efficient of the β-lactam antibi-
otics is cefotaxime, despite the fact that its CER=7.78, 
which is 2.65 times higher than that for amoxicillin/clavu-
lanic acid (CER=2.93).
During the next phase of the study, the clinical and eco-
nomic effectiveness of the macrolides widely used in the 
treatment of acute bronchitis with bronchospasm in the 
hospitalized children was simulated.
The models of costs and efficacy distribution were con-
structed for macrolides (Fig. 3).
The azithromycin groups have the greatest clinical ef-
ficacy (Fig. 3). Midecamycin has the lowest CER among 
macrolides, with a wide scatter of possible clinical effica-
cy. The most expensive of macrolides is a clarithromycin 
course. At the same time, it has a wider scatter of distribu-
tion points. Azithromycin groups have the highest clinical 
efficacy, with the narrowest scatter of distribution points.
To compare the clinical efficacy, the curves of beta-dis-
tribution of the effectiveness of the antibiotics analyzed 
were plotted (Fig. 4).
The azithromycin beta-distribution curve is narrow, sharp-
ly peaked and shifted to the right, indicating the high clini-
cal efficacy of the antibiotic for the treatment of the disease 
studied, which proves the feasibility of using azithromycin.
Table 2. Frequency of positive clinical outcomes*, costs, cost-effectiveness ratio for a course of antibiotic therapy of acute bron-
chitis with bronchospasm.
INN (International 
Nonproprietary Name) Frequency of positive clinical outcomes Cost of the course, US$ CER (cost-effectiveness/efficacy ratio)
Cefotaxime 0.584±0.066 4.54±3.42 7.78
Ceftriaxone 0.546 4.51 8.26
Cefuroxime 0.512 12.82 25.04
Amoxicillin/clavulanate 0.561±0.043 1.66±0.04 2.96
Azithromycin 0.966±0.014 3.52±1.74 3.64
Clarithromycin 0.956±0.011 6.43±4.82 6.73
Spiramycin 0.920 3.35 3.64
Midecamycin 0.850 1.23 1.45
Note: * – presented as a unit fraction
Figure 1. The results of Monte-Carlo cost-effectiveness simula-
tion of the treatment of acute bronchitis with bronchospasm in 
children with β-lactam antibiotics.
Figure 2. Beta-distribution of clinical outcomes for β-lactam 
antibiotics used in the treatment of acute bronchitis with bron-
chospasm in children.
Figure 3. Simulation results of Monte-Carlo cost-effectiveness 
analysis for macrolide antibiotics used in the treatment of acute 
bronchitis with bronchospasm in children.
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However, the values obtained through the simulation 
can vary with different samples of patients. Therefore, at 
the next stage of the study, it was identified how signif-
icant those changes were, and what were the minimum 
ranges covering the exact actual value of the desired fre-
quencies, i.e., a minimum interval that contained the real 
value of the sought for clinical efficacy with a probability 
of 95%, which is known in statistics as the 95% confi-
dence interval (95%CI). In practice, the 95% confidence 
interval means that 95% of the potential samples of the 
drug use for the studied disease will provide the values 
of clinical efficacy that fall within the resulting intervals, 
with only 5% of values lying outside. For this purpose, 
the area under the curve of beta-distribution of clinical 
outcomes for β-lactam antibiotics used in the treatment 
of acute bronchitis with bronchospasm in children was 
found, with 2.5% of the area being cut on the right and on 
the left. The corresponding x values were considered the 
minimum (min (95%)) and the maximum (max (95%)) 
confidential clinical efficacy (Table 3).
The Table shows that cefotaxime is the best β-lactam, 
with the 95% confidence interval of clinical efficacy from 
0.585 to 0.655.
The most optimal of macrolides are azithromycines 
(0.947–0.982), providing the smallest interval of probable 
clinical efficacy for the disease studied.
Conclusion
As the result of the study, it was found that the most ef-
fective antibiotics from the clinical and economic points 
of view in the hospital environment to treat children with 
acute bronchitis with bronchospasm are cefotaxime from 
the beta-lactam group and azithromycin from the macro-
lide group. Also, the study showed that it was preferable 
to use macrolide group antibiotics for treatment of acu-
te bronchitis with bronchospasm. Antibiotics are widely 
used in the pediatric population to treat respiratory disea-
ses, though viruses often act as etiologic agents (Tief et 
al. 2016). In this study, the antibiotic therapy was evalua-
ted in bronchitis complicated with secondary bacterial in-
fection. Antibiotics use for such conditions corresponds 
with the results from other researchers (McCallum et al. 
2017). The first-choice medications for the treatment of 
moderate and severe episodes of bronchitis are protec-
ted beta-lactams and macrolides (Lopardo et al. 2013). 
Macrolides demonstrated the high efficiency in various 
respiratory diseases, especially chronic ones (Spagnolo 
et al. 2013). Laopaiboon M., Panpanich R., Swa Mya 
K. published the results of a search for and analysis of 
randomized clinical trials comparing azithromycin with 
amoxicillin or amoxicillin/clavulanic acid in patients 
with clinically defined acute bronchitis, pneumonia, and 
chronic bronchitis exacerbation. In patients with suspec-
ted acute bacterial bronchitis, azithromycin was found to 
be more effective, regarding a lower probability of tre-
atment failure and adverse effects compared to amoxi-
cillin or amoxicillin/clavulanic acid (Laopaiboon et al. 
2015). The specific feature of macrolides is their effici-
ency against atypical pathogens. Bezerra P.G. Britto MC, 
Correia JB, et al. detected viruses and atypical bacteria 
in all the severity degrees and clinical manifestations 
of respiratory infections, but Mycoplasma pneumonuae 
(along with respiratory syncytial virus) were associated 
with a more severe course of bronchiolitis and pneumo-
nia (Bezerra et al. 2011). Another study was conducted 
to investigate a role of atypical pathogens in the deve-
lopment of asthma in children with acute and recurrent 
obstructive bronchitis with bronchospasm, which found 
the presence of antibodies to atypical pathogens in 32.2% 
of the patients (n=756) (Zhukova et al. 2017). This data 
confirms the usefulness of macrolides in the treatment of 
bronchitis complicated with bronchospasm. The Mon-
te-Carlo method visualizes the results of a clinical-eco-
nomical evaluation of any medical technology in one 
disease compared to another. That is of value for the cli-
nical pharmacologists and health professionals selecting 
the drugs for healthcare facilities.
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Table 3. Probable clinical efficiency of antibiotics used in the treat-
ment of acute bronchitis with bronchospasm in inpatient children.
INN (International 
Nonproprietary Name) Min (95%) Max (95%)
Cefotaxime 0.585 0.655
Ceftriaxone 0.446 0.559
Cefuroxime 0.429 0.602
Amoxicillin/Clavulanic acid 0.472 0.571
Azithromycin 0.947 0.982
Clarithromycin 0.843 0.978
Spiramycin 0.855 0.992
Midecamycin 0.664 0.950
Figure 4. Beta-distribution of outcomes for the macrolides anti-
biotics, used in the treatment of acute bronchitis with bronchos-
pasm in children.
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